Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Great boast, small roast on effects of selective serotonin reuptake inhibitors: response to a critique of our systematic review

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Effects of erythropoietin on body composition and fat-glucose metabolism in patients with affective disorders

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Anaesthesia for electroconvulsive therapy - new tricks for old drugs: a systematic review

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. No effect of escitalopram versus placebo on brain-derived neurotrophic factor in healthy individuals: a randomised trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Association of the leucine-7 to proline-7 variation in the signal sequence of neuropeptide Y with major depression

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Acupuncture for chronic hepatitis B

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Exercise-Based Rehabilitation for Heart Failure: Cochrane Systematic Review, Meta-Analysis, and Trial Sequential Analysis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Plasma expanders for people with cirrhosis and large ascites treated with abdominal paracentesis

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  4. Radix Sophorae flavescentis versus other drugs or herbs for chronic hepatitis B

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

Vis graf over relationer

Our systematic review in BMC Psychiatry concluded that selective serotonin reuptake inhibitors (SSRIs) compared with placebo significantly increase the risk of serious adverse events (SAEs) in patients with major depression and the potential beneficial effects of SSRIs seem to be outweighed by the harms. Hieronymus et al. accused us of methodological inaccuracies and blatant errors. In their post-hoc analysis of our data, they reported that SSRIs only increase the risk of SAEs in elderly and seems safe for non-elderly patients. They also found our review misleading because our efficacy analyses were based on the 17-item Hamilton Depression Rating Scale; we included suboptimal SSRI doses; and we missed some 'pivotal trials'. We do not agree with Hieronymus et al. regarding several of the 'errors' they claim that we have made. However, we acknowledge that they have identified minor errors and that we missed some trials. After rectifying the errors and inclusion of the missed trials by us and Hieronymus et al., we re-analysed the data. The updated analyses are even more robust and confirm our earlier conclusions. SSRIs significantly increase the risk of an SAE both in non-elderly (p=0.045) and elderly (p=0.01) patients [overall odds ratio 1.39; 95% confidence interval (CI) 1.13 to 1.73; p=0.002; I2=0%]. Moreover, SSRIs did not change noticeably the 17-item Hamilton Depression Rating Scale, the internationally accepted scale (mean difference -2.02 points; 95% CI -2.38 to -1.66; p<0.00001). We found no differential effect of dose (p=0.20).

OriginalsprogEngelsk
TidsskriftActa Neuropsychiatrica (Online)
Vol/bind30
Udgave nummer5
Sider (fra-til)251-265
Antal sider15
ISSN1601-5215
DOI
StatusUdgivet - 21 feb. 2018

ID: 52781285